TwinBeech Capital’s ImmunityBio IBRX Stock Holding History

TwinBeech Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-83,765	Closed	-$1.2M	–	671
2021 Q2	$1.2M	Buy	83,765 +56,014	+202%	+$925K	0.15%	192
2021 Q1	$659K	Buy	+27,751	New	+$719K	0.1%	258

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

TwinBeech Capital's IBRX Position: Q3 2021 in Review

TwinBeech Capital sold out of ImmunityBio (IBRX) in Q3 2021, closing a stake of 83,765 shares — an estimated $1.2M sold.

TwinBeech Capital first reported a position in IBRX in Q1 2021 and held it in 2 quarters. The position peaked at $1.2M in Q2 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2021.

TwinBeech Capital reported no remaining ImmunityBio position as of Q3 2021 after selling out during the quarter.
TwinBeech Capital sold 83,765 ImmunityBio shares in Q3 2021, an estimated $1.2M.
TwinBeech Capital first reported a position in ImmunityBio in Q1 2021 and held it in 2 quarters.
TwinBeech Capital's ImmunityBio position peaked at $1.2M in Q2 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.